Dapagliflozin in Respiratory Failure in Patients With COVID-19

NCT04350593 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1250

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Dapagliflozin 10 milligram (mg)
DRUG: Placebo

Sponsor

Saint Luke's Health System

Collaborators

[object Object]
[object Object]
[object Object]